Old Sonic Hedgehog, new tricks: a new paradigm in thoracic malignancies
Metrics: PDF 735 views | HTML 2141 views | ?
Etienne Giroux Leprieur1,2, David M. Jablons3 and Biao He3
1Department of Respiratory Diseases and Thoracic Oncology, APHP - Ambroise Paré Hospital, Boulogne-Billancourt, France
2EA 4340 BCOH, UVSQ, Paris-Saclay University, Boulogne-Billancourt, France
3Thoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA
Etienne Giroux Leprieur, email: Etienne.email@example.com
Keywords: Sonic Hedgehog; lung cancer; mesothelioma; cancer stem cell; chemoresistance
Received: November 11, 2017 Accepted: January 25, 2018 Epub: February 06, 2018 Published: March 06, 2018
The Sonic Hedgehog (Shh) pathway is physiologically involved during embryogenesis, but is also activated in several diseases, including solid cancers. Previous studies have demonstrated that the Shh pathway is involved in oncogenesis, tumor progression and chemoresistance in lung cancer and mesothelioma. The Shh pathway is also closely associated with epithelial-mesenchymal transition and cancer stem cells. Recent findings have revealed that a small proportion of lung cancer cells expressed an abnormal full-length Shh protein, associated with cancer stem cell features. In this paper, we review the role of the Shh pathway in thoracic cancers (small cell lung cancer, non-small cell lung cancer, and mesothelioma) and discuss the new perspectives of cancer research highlighted by the recent data of the literature.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.